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Background: Renal dysfunction is common after car-
diopulmonary bypass procedures and is associated with
higher mortality rates and longer lengths of stay.
However, less is known about the actual cost of care for
these patients. We sought to quantify the hospital costs
attributed to renal dysfunction in cardiopulmonary
bypass patients at a large academic referral center.
Methods: All patients undergoing cardiopulmonary
bypass procedures were identiﬁed through administrative
databases for a 3-year study period. Renal failure was
deﬁned using laboratory values from the hospitalization.
Total direct costs and costs by hospital department were
determined using the hospital cost-accounting system. A
multivariate linear model was developed to determine
total direct hospital costs after cardiopulmonary bypass
procedures after adjusting for relevant clinical and demo-
graphic variables.
Results: Nine percent of the study population developed
new-onset renal dysfunction, and 18% of patients overall
undergoing cardiopulmonary bypass experienced renal
dysfunction during the hospitalization. Direct costs were
42% higher for patients with renal dysfunction, an
average of $5807 per case. Higher costs were noted in
intensive care unit use and pharmacy, laboratory, and
radiology services.
Conclusions: Renal dysfunction increases the direct hos-
pital costs of care, even after adjustment for age, sex, race,
and comorbidities. Nationwide, we estimate that renal
dysfunction may add up to $643 million in hospital costs
for caring for cardiopulmonary bypass patients. Inter-
ventions designed to reduce the incidence and severity of
renal dysfunction may signiﬁcantly reduce hospital costs
for these patients.
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ABSTRACT
Introduction
Cardiopulmonary bypass surgical procedures are
common and expensive and may have signiﬁcant
complications associated with the procedure. For
example, coronary artery bypass grafting (CABG)
annually accounts for an estimated 607,000 opera-
tions, with an average total cost per case of $44,820
[1]. Over the past 20 years, the volume of CABG
procedures has grown markedly, with the most sig-
niﬁcant growth occurring among older patient pop-
ulations [2–7]. Between 1987 and 1996, for
example, CABG rates in the United States rose by
18% among patients aged 65 years or older and by
67% among those aged 80 years or older [8,9].
Coincident with this older demographic is a patient
population that has a higher burden of cardiac and
noncardiac comorbid illness [10] as well as higher
rates of postsurgical complications.
Major complications after cardiopulmonary
bypass include myocardial infarction, stroke, and
renal failure and are generally the result of insuf-
ﬁcient end-organ perfusion during cardiopul-
monary bypass [11–13]. Hammermeister et al. [14]
evaluated over 10,000 patients undergoing CABG
at Veterans Administration medical centers between
1987 and 1989. In this study, investigators found
that 15% of patients had one or more ischemia-
related complications. In terms of renal impairment
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speciﬁcally, several studies have shown that patients
who have undergone cardiac surgery develop
decreased renal blood ﬂow and signiﬁcantly
reduced glomerular ﬁltration rates [15–17]. The
impact of these phenomena on clinical and cost out-
comes are not well understood but are thought to
be considerable.
Acute renal failure is a frequent complication 
of operations utilizing cardiopulmonary bypass
[18–21]. Moderate reversible renal dysfunction
occurs after 30% of these procedures and is associ-
ated with mortality rates ranging from 7% to 38%
[16,20–23]. However, approximately 5% of post-
cardiopulmonary bypass patients will develop
severe postsurgical renal failure requiring hemodial-
ysis. In this latter subgroup, all-cause mortality is
considerably higher and ranges from 50% to 90%
[10,16,20–22]. Mortality among these patients
requiring acute hemodialysis is attributable not only
to a loss of renal function but also to high rates of
secondary complications, such as central nervous
system dysfunction, sepsis, and gastrointestinal
bleeding [23,24].
Despite the impact that renal dysfunction has on
clinical outcomes and length of stay [13], relatively
little is known about the economic consequence of
renal dysfunction after cardiopulmonary bypass
surgery. Prior studies analyzing the costs associated
with CABG surgery have generally identiﬁed two
populations of patients—“low-cost” ($16,000–
$20,000) and “high-cost” ($40,000–$80,000) sub-
groups [25]. Costs in the high-cost subgroup, not
surprisingly, have been shown to be driven by severe
and usually multiple postoperative complications.
However, the speciﬁc role of renal dysfunction on
hospital costs is unknown.
The purpose of this study was threefold: 1) to
estimate the impact of renal dysfunction on total
direct hospital costs in cardiopulmonary bypass
patients; 2) to stratify that analysis by the type of
renal dysfunction, and 3) to identify which hospital
cost centers were the primary drivers of increased
costs associated with renal dysfunction.
Methods
Setting, Patient Selection, and Data Sources
The setting for this study was New York Presbyter-
ian Hospital–Weill Cornell Campus, a tertiary care
academic medical center in New York City. Using
administrative data, we identiﬁed all patients (N =
3493) undergoing cardiopulmonary bypass proce-
dures based on DRG assignment (DRGs 104–107
and 109) for the study years 1998 to 2000. Patients
under the age of 18 and with missing cost data were
excluded.
Serum creatinine values were collected on the
entire population (N = 3493) and used to classify
cases into one of four renal function categories as
described later. We then selected a random sample
of 1000 cases, representing 28% of myocardial
revascularization procedures performed during the
study period. Thirty-one cases were excluded based
on the above criteria, leaving a total study sample
of 969 cases. No statistically signiﬁcant clinical or
demographic differences were observed between
our study sample (N = 969) and our base popula-
tion (N = 3493) (data not shown). To have sufﬁ-
cient samples in each of the four study subgroups
(see deﬁnitions of renal dysfunction later), we over-
sampled for patients with renal dysfunction.
Serum creatinine values, used to classify cases
into one of four renal function categories, were
obtained from the clinical information system.
Demographic data, ICD-9 codes, total direct hospi-
tal costs, and direct costs by hospital cost center
were electronically obtained from an institutional
administrative and cost accounting data set (The
Transition Systems, Inc. [TSI], Iowa City, IA).
An IRB exemption was obtained for this study,
because the data collection was limited to anony-
mous retrospective administrative data review.
Deﬁnitions of Renal Dysfunction and Comorbidity
Classiﬁcations
Serum creatinine values were obtained by manual
review of laboratory data for each case included in
our sample. Hospital admission dates for myocar-
dial revascularization procedures were matched to
corresponding laboratory data. For each hospi-
talization, three serum creatinine values were
recorded: 1) admission serum creatinine; 2) highest
serum creatinine during the hospitalization, and 3)
discharge serum creatinine. Cases were then classi-
ﬁed into one of four categories based on the fol-
lowing criteria: 1) normal renal function—all three
serum creatinine measurements £1.5mg/dl; 2)
presurgical renal dysfunction (stable)—admission
creatinine >1.5mg/dl and other two measurements
did not exceed 25% of baseline admission creati-
nine; and 3) presurgical renal dysfunction (worsen-
ing)—admission creatinine >1.5mg/dl and at least
one of the other two creatinine measurements
exceeded baseline admission creatinine by 25%;
and 4) postsurgical renal dysfunction—admission
creatinine measurement £1.5mg/dl and at least one
of the other two creatinine measurements
>1.5mg/dl. Comorbidity illness classiﬁcation was
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determined using ICD-9 description codes and the
comorbidity scale of Charlson et al. [26] as modi-
ﬁed by Deyo et al. [27].
Cost Identiﬁcation Methods
All costs are presented in FY2000 USD using the
M-CPI and obtained after patient discharge. Cost
data were electronically acquired from TSI, the
institutional cost-accounting system. In TSI, costs
are derived from individual patient charges with the
application of department-speciﬁc cost-to-charge
ratios used for Medicare reporting [28,29]. Total
direct costs were deﬁned according to the TSI
format and included all patient service, nursing, and
technical personnel costs as well as supplies.
TSI includes several hundred cost centers; these
cost centers were consolidated into 18 department-
level cost centers to analyze the main drivers of
costs in patients with renal dysfunction. Addition-
ally, for this analysis, direct medical costs included
costs for the use of inpatient wards, operating
rooms, intensive care units (ICUs), pharmaceuticals,
laboratory services, and radiologic services. All pro-
fessional fees were excluded.
Statistical Methods
We used descriptive statistics (SAS System v6.12,
SAS Institute Inc., Cary, NC) to characterize our
study population. For this analysis, our dependent
outcome of interest was total direct hospital costs
(log TDHC). Univariate measures of association
were then tested between our primary outcome
variable, log TDHC, and each of the demographic
and clinical independent variables. The demo-
graphic variables included age, sex, and race (white
vs. nonwhite). Clinical variables included renal
function classiﬁcation and comorbidity score (see
above: “Deﬁnitions of Renal Dysfunction and
Comorbidity Classiﬁcations”).
Univariate measures of association for categori-
cal variables were calculated using Fisher’s exact
test. Univariate measures of association for contin-
uous variables were tested using either Student’s 
t test (parametric) or Wilcoxon’s rank sum (non-
parametric) test. A multivariable linear model was
then developed to generate the adjusted geometric
means for log TDHC, our dependent variable. To
improve the efﬁciency of the statistical model, we
employed a log transformation to TDHC to follow
the implicit statistical assumptions of normality.
Using a general linear model (Proc GLM), we
selected the best model by applying a stepwise
regression with a threshold of P £ .01 for selection
and stay. The ﬁnal multivariable model included
age, sex, race, comorbidity score, and renal dys-
function category. There were no statistically sig-
niﬁcant interaction terms identiﬁed in the model.
Collinearity diagnostics were performed with a
detailed analysis of collinearity among the regres-
sors including eigenvalues, condition indexes, and
decomposition of the variances of the estimates
with respect to each eigenvalue, and there was no
resulting evidence of multicollinearity. No explana-
tory variable was found to be a near-linear combi-
nation of other explanatory variables in the model.
Speciﬁcally, no component of the model was asso-
ciated with a condition index greater than 18
(whereas a condition index of 30–100 indicates
moderate-to-strong collinearity).
We also tested the model for heteroskedasticity
(i.e., increasing or decreasing variation in the resid-
uals with ﬁtted values) using ﬁtted values of log
TDHC by ﬁrst examining a plot of the residuals
versus the ﬁtted values. No unusual pattern was 
discerned from this plot. As well, we performed 
the Cook-Weisberg test for heteroskedasticity using
ﬁtted values of log TDHC, and there was no evi-
dence to suggest a departure from the null hypoth-
esis of constant variance (P > .05).
Least-squares means and their respective 
conﬁdence intervals (CIs) are presented as back-
transformed (exponentiated) values (i.e., geometric
means). We also report pairwise comparisons of the
adjusted geometric means for log TDHC between
each of the four renal function subgroups. All pre-
sented P values are two-tailed with statistical sig-
niﬁcance evaluated at the 0.05 alpha level.
Results
A schematic of our study sample is shown in Fig. 1.
From the original 3-year study population (N =
3493), 633 patients (18%) undergoing cardiopul-
monary bypass experienced renal dysfunction
during the surgical hospitalization period. Approx-
imately half of these patients (N = 311; 49%) de-
veloped new-onset renal dysfunction. From this
population, we then selected a random sample of
cases, oversampling for patients with renal dys-
function to have a sufﬁcient sample in each of the
four study subgroups for our cost analysis.
Table 1 shows the demographic and clinical char-
acteristics of the study population. The overall rate
of renal dysfunction in the cardiopulmonary bypass
population at our study institution was 18% after
adjusting for the oversampling of patients with
renal dysfunction. Patients were stratiﬁed into 
four groups as previously deﬁned: 1) normal renal
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function, 2) presurgical renal dysfunction (stable);
3) presurgical renal dysfunction (worsening); and 4)
postsurgical renal dysfunction. From these data,
patients with renal dysfunction were more likely to
be female, older, and members of minority groups.
Furthermore, the comorbidity scores were higher in
patients with renal dysfunction than in patients
without renal impairment. Renal dysfunction was
also associated with longer unadjusted lengths of
stay and higher in-hospital mortality rates for all
three subgroups when compared to patients with
normal renal function.
We next examined which demographic and clin-
ical characteristics were associated with increased
total direct hospital costs. Age, sex (being female),
higher comorbidity score, nonwhite race, and renal
dysfunction were all signiﬁcantly associated with
higher costs (data not shown). A multivariate 
linear model of log TDHC was developed as
described above. In this model, age, sex, race, renal
dysfunction, and comorbidity score remained 
and were used to produce adjusted total direct
costs. The parameters of this model are shown in
Table 2. Renal dysfunction demonstrated the
strongest univariate association with total direct
costs (P < .001) and was used to guide our strati-
ﬁed analysis.
We stratiﬁed our cost analysis by renal function
classiﬁcation and report risk-adjusted geometric
means and 95% CI as described above. As shown
in Fig. 2, in patients with normal renal function, the
TDHC averaged $13,708 (mean $12,944; 95% CI
$14,519) after cardiopulmonary bypass procedures.
For patients with new-onset, postsurgical renal 
dysfunction, the THDC averaged $18,834 (mean
$17,049; 95% CI $20,805), increasing costs by
34% when compared to normal patients. Patients
with pre-existing renal dysfunction demonstrated
worse economic outcomes. Patients with presurgi-
cal but stable renal dysfunction averaged $19,539
(mean $17,713; 95% CI $21,553) in adjusted
TDHC, while patients with presurgical but wors-
ening renal dysfunction averaged $22,110 (mean
$19,848; 95% CI $24,631). Further, all renal dys-
function models demonstrated statistically signiﬁ-
cant differences in adjusted log TDHC when
Table 1 Clinical and demographic characteristics of study population
Presurgical RD
Normal renal Postsurgical
Total* function* RD* Stable* Worsening*
N (% of total)†* 969 (100) 576 (59.4) 145 (15) 136 (14) 112 (11.6)
Age (years) 67.89 ± 11.70 66.36 ± 11.62 72.05 ± 10.58‡ 67.96 ± 11.89 70.30 ± 11.74‡
% Female 32.30 37.15 22.07‡ 30.15 23.21§
Comorbidity score 1.01 ± 1.07 0.81 ± 0.94 1.19 ± 1.08‡ 1.42 ± 1.34‡ 1.28 ± 1.13‡
Admit creatinine 1.69 ± 1.85 0.90 ± 0.25 1.18 ± 0.24‡ 4.35 ± 3.09‡ 3.17 ± 1.80‡
Peak creatinine 2.17 ± 2.27 1.05 ± 0.23 2.15 ± 0.79‡ 4.58 ± 3.31‡ 5.07 ± 2.0‡
% Minority 33.95 33.50 26.21 36.03 43.75
Length of stay (days) 11.76 ± 7.12 9.71 ± 4.97 14.48 ± 8.55‡ 13.21 ± 7.17‡ 17.05 ± 9.74‡
Mortality (%) 3.41 0.70 5.52‡ 6.62‡ 10.71‡
Mean direct cost 18,238 ± 13,405 14,972 ± 11,015 21,733 ± 14,246‡ 22,864 ± 15,504‡ 24,890 ± 15,515‡
(unadjusted)
Note: Clinical and demographic characteristics of four study subgroups: 1) normal renal function; 2) postsurgical renal dysfunction; 3) presurgical renal dysfunction
(stable); and 4) presurgical renal dysfunction (worsening). Deﬁnitions for the four subgroups can be found in the text. Statistical signiﬁcance reﬂects pairwise com-
parisons to the normal renal function subgroup. Statistical comparisons were made using the following analyses: 1) Student’s t test (age, comorbidity score, admit
creatinine, peak creatinine, and mean direct cost); 2) chi-square (% female and % minority); and 3) Wilcoxon rank-sum (length of stay).
*Mean ± SD.
†Study population is oversampled for renal dysfunction.
‡P £ .0001.
†P < .001.
Abbreviation: RD, renal dysfunction.
Analytic Sample
N=969
Postsurgical
N=309 (9%)
Presurgical
N=324 (9%)
Total in hospital
renal dysfunction
N=633 (18%)
Postsurgical
N=145 
Presurgical
(stable)
N=136
Presurgical
(worsening)
N=112
Total  Population
N=3493
Non-renal
dysfunction
N=2860
Non-renal
dysfunction
N=576 
Figure 1 Schematic of total population and analytic sample. Total
population represents all adult patients (N = 3493) undergoing car-
diopulmonary bypass procedures based on DRG assignment (DRGs
104–107 and 109) for the study years 1998–2000. Analytic sample
represents a random sample of 1000 cases (28% of total population),
oversampled for patients with renal dysfunction. Subgroup classiﬁca-
tions and deﬁnitions of renal dysfunction are given in the text.
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compared to the normal renal function model 
(P < .001).
We next examined the sources of increased costs
for all patients with renal dysfunction compared to
patients with normal renal function. In this analy-
sis, we identiﬁed several important drivers of the
increased cost associated with renal dysfunction,
including ICU costs ($6764 vs. $3988), pharmacy
($2191 vs. $952), laboratory testing ($1167 vs.
$728), and radiology services ($441 vs. $247) (P <
.05 for all comparisons). Operating room costs
were not signiﬁcantly different between the two
groups ($5587 vs. $5010). The 13 other depart-
ment-level cost centers were similar between 
subgroups.
Renal dysfunction patients in all three subgroups
also incurred signiﬁcantly longer lengths of stay and
higher mortality rates compared to patients with
normal renal function. However, the lengths of stay
and the mortality rates reported here are unadjusted
and warrant further examination.
Discussion
Our study demonstrated that 18% of patients
undergoing cardiac bypass surgical procedures
developed or had pre-existing renal dysfunction.
These patients incurred signiﬁcantly higher direct
hospital costs compared to patients with normal
renal function after adjusting for patient age, sex,
comorbidities, and race. Longer lengths of stay,
higher use of ICU services, more laboratory and
radiology testing, and higher pharmacy costs likely
drive the higher costs.
These data are consistent with prior studies eval-
uating the economic impact of major complications
after bypass surgery. In a single-institution study,
Naglie and colleagues [30] reported $15,600 in
direct hospital costs for elective, uncomplicated
bypass patients. In contrast, elective patients with
signiﬁcant postsurgical complications averaged
$23,700 in direct hospital costs. Although in this
study major postsurgical complications were
broadly deﬁned, these data are of the same relative
magnitude as are the data reported here. Similarly,
Mangano et al. [22] report increased hospital-based
resource utilization among patients with renal dys-
function after cardiopulmonary bypass surgery. In
that study, patients with renal failure had more days
in the ICU (6.5 vs. 3.1 days) and signiﬁcantly longer
hospital stay (18.2 vs. 10.6 days). Additionally,
renal patients were three times as likely to be dis-
charged to a long-term care facility.
There are several limitations that must be con-
sidered when interpreting this study. We include
only hospital direct costs in this study. Professional
fees billed by physicians are not included, nor are
hospital indirect costs (which are difﬁcult to inter-
pret). Additionally, this is a single-institution study,
and the costs reported are relevant to this par-
ticular institution. However, the magnitude of the
increased costs is consistent with prior studies and
may be generalizable to other institutions. The rate
Table 2 Multivariate model of total direct hospital costs
Beta Standard 
Independent variable coefﬁcient error P value
Age* 0.0065 0.0016 <.0001
Sex† 0.1768 0.0397 <.0001
Race‡ 0.0616 0.0395 .12
Comorbidity score
1§ 0.0875 0.0427 .04
2§ 0.1784 0.0545 .001
≥3§ 0.1866 0.0716 .009
Postsurgical renal disease|| 0.3213 0.0541 <.0001
Presurgical renal disease
Stable|| 0.3550 0.0551 <.0001
Worsening|| 0.4787 0.0599 <.0001
Note: A multivariable linear model was then developed to generate the
adjusted geometric means for log TDHC, our dependent variable. Covariates
included in the ﬁnal model included age, sex, race, and comorbidity score (clas-
siﬁcation of Deyo et al. [27]) and renal dysfunction category. Model parame-
ters and P values are shown.
*Treated as a continuous variable in model.
†Male (referent) vs. female.
‡White (referent) vs. nonwhite.
§Referent group: comorbidity score = 0.
||Referent group: normal renal function.
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Figure 2 Hospital cost associated with renal dysfunction after car-
diopulmonary bypass surgery. Least-squares means and their respec-
tive 95% CIs are presented for each study subgroup: 1) normal renal
function; 2) postsurgical renal dysfunction; 3) presurgical renal dys-
function (stable); and 4) presurgical renal dysfunction (worsening).
Deﬁnitions for the four subgroups can be found in the text.All cost
data are presented as back-transformed (exponentiated) values (i.e.,
geometric means). We also report pairwise comparisons of the
adjusted means for log TDHC to the normal renal function subgroup.
*For each preplanned group comparison with the normal group (on
the log scale), all P values are < .0001. RD, renal dysfunction.
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of renal failure also may be different at other insti-
tutions; the study site is a large academic medical
center and receives many complicated referrals as
well as re-operations, which may increase the risk
of renal failure. Finally, owing to inherent limita-
tions in our administrative data set, we were unable
to identify hemodialysis status among our presurgi-
cal subgroups. Thus, these presurgical subgroups
(presurgical subgroups [stable] and presurgical
[worsening]) contain a mixture of patients with
chronic renal insufﬁciency and chronic renal failure
requiring hemodialysis.
In our study, cardiopulmonary bypass patients
with renal dysfunction averaged $5807 higher costs
per admission compared to patients with normal
renal function. This cost difference translates to
$3.7 million in additional costs incurred by the
study institution over the 3-year study period,
approximately half of which is attributable to new-
onset postsurgical renal dysfunction. This latter
postsurgical subgroup, the 9% of patients admitted
with normal renal function who developed renal
dysfunction during their hospitalization, is an
important subgroup because it is in this postsurgi-
cal subgroup that prevention of the renal dysfunc-
tion may signiﬁcantly reduce direct hospital costs.
Additionally, our data conﬁrm that patients with
pre-existing but stable renal dysfunction demon-
strate signiﬁcantly greater total direct hospital costs
than do normal controls and that patients with pre-
existing but worsening renal dysfunction are more
costly still. From an economic perspective, these
data highlight the importance of clinical strategies
that optimize renal function in all patients that
undergo cardiopulmonary bypass surgery. Such
interventions could potentially include: 1) improved
preoperative screening to identify high-risk patients;
2) improved monitoring of intraoperative and 
postoperative volume status; 3) careful avoidance 
of nephrotoxic agents; and ﬁnally 4) pharmaco-
logic interventions that improve glomerular 
ﬁltration and renal blood ﬂow, thereby providing a
physiologic environment of heightened renovascu-
lar protection.
Conclusion
From the data presented, we conclude that inter-
ventions that reduce the incidence of renal dys-
function, or that ameliorate the worsening of
pre-existing renal dysfunction, may be signiﬁcantly
cost saving. Nationwide there are 607,000 cardiac
bypass graft surgeries done on an annual basis.
Using data from this investigation, we estimate that
the increased hospital direct costs associated with
renal dysfunction for cardiopulmonary bypass
patients across the United States is approximately
$643 million. These incremental costs are primarily
borne by hospitals, who under most reimbursement
methodologies are unable to bill patients or payers
for these additional expenditures. Thus interven-
tions or pharmacotherapies that can reduce the inci-
dence of renal dysfunction in patients undergoing
cardiopulmonary bypass procedures are likely to be
cost-effective.
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